GSK GSK plc

   By Dominic Chopping 
 

Danish pharmaceutical company Genmab A/S (GEN.KO) said Wednesday that net sales of the Arzerra (ofatumumab) treatment for chronic lymphocytic leukaemia by GlaxoSmithKline PLC (GSK) and Novartis AG (NVS) during the first quarter of 2015 were GBP11.1 million.

This figure consists of net sales in the U.S. of GBP6.0 million and in the rest of the world of GBP5.1 million.

Under the terms of the collaboration with Novartis Pharma AG, Genmab expects to receive a royalty payment of approximately DKK22 million.

Arzerra is marketed under a co-development and collaboration agreement between Genmab and Novartis, who acquired an interest in the drug from GSK earlier this year.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires